Company
Company

Relevant Interviews, Webinar and Trial Updates posted by CRISPR Medicine News.

Always stay updated with the free CMN Newsletter.

GenEditBio

Main focus: Developing safe and effective in vivo gene-editing therapies

Company stage: Pre-clinical

Diseases: Liver diseases and other undisclosed targets

Genome-editing tool: Novel Cas nucleases

Funding stage: Pre-A+

Location: Hong Kong, Hong Kong Island, Hong Kong

Website: GenEditBio

Pipeline: https://www.geneditbio.com/pipeline

Partners:

GenEditBio is a biotechnology company that specialises in gene-editing technologies to develop treatments for diseases that lack effective treatments. The company's goal is to develop a robust gene-editing platform to create safe and efficient therapeutic solutions. GenEditBio primarily focuses on in vivo gene therapies, with future plans to expand into ex vivo gene-edited cell therapies. GenEditBio’s pipeline currently includes five programmes addressing liver tissue and other undisclosed targets.

Tags

HashtagGenEditBio

Company: GenEditBio
close
Search CRISPR Medicine